key: cord-0768794-l6fizbt0
authors: Khiali, Sajad; Entezari-Maleki, Taher
title: Anticoagulation in COVID-19: DDI Perspective
date: 2020-09-16
journal: Clin Appl Thromb Hemost
DOI: 10.1177/1076029620959457
sha: 5e109e2f1deaf05df05f0c51f54697d81f18230d
doc_id: 768794
cord_uid: l6fizbt0

nan

The novel 2019 coronavirus disease (COVID-19) creates a hypercoagulable state in which thrombotic microangiopathy, and a local disseminated intravascular coagulation (DIC) tends to be the principle cause of death. The COVID-19 hyperinflammatory state, and inflammatory cytokine releasing, mainly IL-6, is associated with the down-regulation of drugmetabolizing enzymes and transporters activity. During the 1980 influenza epidemic, a clinically significant inflammationinduced loss of CYP1A2 activity led to theophylline toxicity in children. [1] [2] [3] [4] Notably, drug-drug interactions (DDIs) described here are mainly based on proposed mechanisms of CYP and transporter inhibitory/induction properties.

Considering the key role of the inflammation in the pathogenesis of COVID-19, several immunomodulatory agents are being investigated. TNF-a, IL-1, and IL-6 blocker agents decrease the effects of anticoagulants due to cytochrome P450 enzymes induction. Among them, DDIs of IL-6 inhibitors have attracted the greatest interest. The American Society of Hematology recommended that apixaban and rivaroxaban should not be used with sarilumab and tocilizumab. Moreover, interferon-induced suppression effects on hepatic CYP450 enzymes and consequent drug interactions should be also considered. For example, warfarin dose reduction may be needed. Furthermore, Dexamethasone an inducer of P-glycoprotein in pre-clinical models, and a moderate inducer of CYP3A4. Consequently, its DDIs with anticoagulants should be considered. In the coadministration of warfarin with methylprednisolone, a decreasing dose of warfarin may be required.

Protease inhibitors such as ritonavir/lopinavir and atazanavir have been considered for off-label use in the treatment of COVID-19. These active substances are strong inhibitors of both CYP3A4 and P-glycoprotein and therefore may increase plasma concentrations of factor Xa (FXa) inhibitors to a clinically relevant degree, leading to an increased bleeding risk. Rivaroxaban should be avoided in this treatment scenario, while dose adjustment of warfarin edoxaban, apixaban, and betrixaban may be considered based on the current labeling.

Anti-hepatitis C virus nucleoside analogs including ribavirin, sofosbuvir, and daclatasvir are being investigated for the COVID-19 management. Among them, ribavirin may reduce the anticoagulant effect of warfarin through decreasing warfarin absorption. There is no predicted DDI between daclatasvir and warfarin; however, daclatasvir is a P-glycoprotein inhibitor, and predicted to decrease the metabolism of FXa inhibitors and dabigatran.

Azithromycin could increase the serum concentrations of dabigatran, betrixaban, and edoxaban through P-glycoprotein/ ABCB1 inhibition, and the serum concentration of warfarin through unknown mechanisms. Furthermore, among antiparasitic agents, nitazoxanide with probable effects in COVID-19 could increase the warfarin level through protein binding competition (Table 1) .

To date, no major DDI has been identified between the COVID-19 investigational agents and parenteral anticoagulants including heparin, low molecular weight heparin, fondaparinux, desirudin, danaparoid, bivalirudin, and argatroban due to their non-CYP-mediated metabolism. Besides, no major DDI has been recognized between other agents including remdesivir, favipiravir, sofosbuvir, chloroquine/hydroxychloroquine, pirfenidone, losartan, fingolimod, bevacizumab, and eculizumab with oral anticoagulants. [5] [6] [7] [8] [9] [10] Taken together, based on current evidence, parenteral anticoagulants have lower DDIs than oral anticoagulants. Besides, considering metabolism pathways of oral anticoagulants, edoxaban, betrixaban, and dabigatran are less likely to interact with COVID-19 drugs. Finally, hospitalized patients with COVID-19 should be monitored regarding anticoagulation using clinical and laboratory criteria and potential DDIs. 

Coagulation abnormalities and thrombosis in patients with COVID-19

Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Regulation of drugmetabolizing enzymes and transporters in infection, inflammation, and cancer

Liverpool COVID-19 Interactions. COVID-19 Drug Interactions. Revised 2020

Xarelto (rivaroxaban)

Eliquis (apixaban)

A review of daclatasvir drugdrug interactions